(firstQuint)A Study of Indinavir Taken With or Without DMP 266.

 In this double-blind, placebo-controlled study, 300 patients are randomized to 1 or 2 reverse transcriptase inhibitors of their choice plus blinded therapy on Arm A or B as follows: Arm A: DMP 266 placebo plus indinavir.

 Arm B: DMP 266 plus indinavir.

 After 16 weeks, patients may switch the NRTI portion of their regimen if they meet a treatment failure criterion.

 After the completion of the 24-week period, patients have the option to continue on open-label DMP 266 and indinavir.

.

 A Study of Indinavir Taken With or Without DMP 266@highlight

The purpose of this study is to see if it is safe and effective to add DMP 266 to an anti-HIV treatment program of indinavir and nucleoside reverse transcriptase inhibitors (NRTIs).

